| Literature DB >> 26927018 |
Eifion Robinson1, Emily Knight1, Natalia Smoktunowicz2, Rachel C Chambers2, Graham G Inglis3, Vijay Chudasama1, Stephen Caddick1.
Abstract
The discontinuation of PAR-1 antagonist RWJ-58259 beyond use as a biological probe is most likely due to it's short half-life in vivo. However, retention of significant in vivo activity beyond the point where most of the RWJ-58259 had been consumed implies the generation of an active metabolite. Herein we describe the biological activity of a predicted metabolite of RWJ-58259 and the synthesis of analogues designed to enhance the metabolic stability of RWJ-58259.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26927018 DOI: 10.1039/c6ob00332j
Source DB: PubMed Journal: Org Biomol Chem ISSN: 1477-0520 Impact factor: 3.876